Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
272.64
-4.69 (-1.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
June 13, 2024
Via
Benzinga
Behind the Scenes of Alnylam Pharmaceuticals's Latest Options Trends
June 12, 2024
Via
Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
June 05, 2024
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.
Via
InvestorPlace
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
May 17, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 09, 2024
Via
Benzinga
ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
ALNY stock results show that Alnylam Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
How Is The Market Feeling About Alnylam Pharmaceuticals?
April 19, 2024
Via
Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Alnylam Pharmaceuticals's Earnings Outlook
February 14, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
April 09, 2024
Via
Benzinga
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
April 08, 2024
The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood...
Via
Benzinga
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
April 02, 2024
Via
Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
3 Biotech Stocks to Buy on the Dip: March 2024
March 27, 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Via
InvestorPlace
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
February 06, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
March 18, 2024
Via
Benzinga
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via
InvestorPlace
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
March 09, 2024
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung...
Via
Talk Markets
Exposures
Product Safety
Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges
March 05, 2024
Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in blood pressure observed, with optimistic outlook on upcoming ACC event.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
February 29, 2024
Via
Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
February 28, 2024
Via
Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
Via
Investor's Business Daily
Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know
February 16, 2024
Via
Benzinga
Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?
February 15, 2024
Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.
Via
Benzinga
Exposures
Product Safety
Why Alnylam Pharmaceuticals Stock Is Sinking Today
February 15, 2024
Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.
Via
The Motley Fool
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
January 12, 2024
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.
Via
Investor's Business Daily
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
January 04, 2024
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...
Via
Benzinga
Topics
ETFs
10 Health Care Stocks Whale Activity In Today's Session
January 02, 2024
Via
Benzinga
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
December 29, 2023
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.
Via
Benzinga
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
December 22, 2023
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.